Doctors injected one tumor and watched cancer vanish from the entire body, offering real hope against the disease that claims millions of American lives yearly.
Story Highlights
- Rockefeller University researchers achieved complete remission in 2 of 12 metastatic cancer patients by injecting a single tumor with 2141-V11 immunotherapy.
- Non-injected tumors shrank or disappeared across the body due to the abscopal effect, proving systemic immune activation from local treatment.
- Direct intratumoral injection eliminates severe toxicity that plagued past CD40 therapies, solving a decades-old problem.
- Trials now expanding to nearly 200 patients, targeting tough cancers like glioblastoma and prostate cancer.
- Tertiary lymphoid structures form in tumors, turning them into immune hubs that fight cancer body-wide.
Breakthrough Delivery Method Transforms Cancer Treatment
Researchers at Rockefeller University developed 2141-V11, a modified CD40 agonist antibody. They inject it directly into one tumor instead of using intravenous delivery.
In a phase 1 trial published in Cancer Cell, 12 patients with metastatic cancers received treatment. Six patients saw tumor shrinkage. Two achieved complete remission, with all detectable cancer gone.
Jeffrey Ravetch led the team at the Leonard Wagner Laboratory. This approach concentrates the drug at the tumor site and activates immune cells locally while sparing healthy tissues.
Past CD40 therapies failed due to severe systemic toxicity from widespread receptor activation. Direct injection overcomes this barrier. Patients experienced only mild side effects. No severe adverse events occurred in the trial.
Breakthroughs like this are why sustained investment in biomedical science matters.
In an early trial, injecting immunotherapy into one tumor triggered immune responses across the body – with 50% of patients responding and some complete remissions.
Science saves lives. pic.twitter.com/V26f705tou
— Dr. Catharine Young (@DrCatharineY) March 18, 2026
Abscopal Effect Delivers Body-Wide Cancer Destruction
One melanoma patient had dozens of metastatic tumors on her leg and foot. Doctors injected only one tumor on her thigh multiple times. All other tumors disappeared.
This abscopal effect shows the injected site’s immune response spreads systemically. Treated tumors develop tertiary lymphoid structures, immune cell clusters mimicking lymph nodes.
These structures include dendritic cells, T cells, and B cells. They turn immunosuppressive tumors immunogenic. The effect extends to distant, non-injected sites.
Juan Osorio, first author and oncologist at Memorial Sloan Kettering, called the remissions remarkable. High T cell clonality at baseline predicted complete responses in winners. Researchers now study these biomarkers to select patients.
Trials Expand as Immunotherapy Renaissance Builds Momentum
Phase 1/2 trials now enroll nearly 200 patients at sites such as Memorial Sloan Kettering and Duke University. They test 2141-V11 against bladder, prostate, and glioblastoma cancers.
Parallel advances bolster hope. UCLA’s CAR-NKT cells killed pancreatic tumors in preclinical work, eyeing FDA trials. KAIST converts tumor macrophages into killers in situ.
Five-year survival for advanced cancers hit 70%. Metastatic melanoma jumped from 16% to 35% over 25 years via checkpoint inhibitors. Dr. Antoni Ribas notes immunotherapy’s direct impact.
Under President Trump’s focus on American innovation, these private-led breakthroughs cut red tape. They promise faster access without bloated government spending.
Ravetch’s innovation fixes delivery, not the drug. It aligns with conservative values of practical, American ingenuity over wasteful systemic failures.
Families gain real weapons against cancer’s toll. Phase 2 data will confirm if early wins scale. Patients with aggressive cancers stand to benefit most. This validates intratumoral strategies for broader immunotherapies.
New Cancer Immunotherapy Killed Whole Tumors
Researchers at Rockefeller University are reporting encouraging results from an early clinical trial of a redesigned cancer immunotherapy that is injected directly into tumors.
In the small study, six of 12 patients experienced…
— NENE'S MOMMA (@DebrulerTerri) March 18, 2026
Sources:
Fox News – New cancer therapy hunts and destroys deadly tumors in major breakthrough: study
ScienceDaily – KAIST researchers develop in situ CAR-macrophages
Cancer Research Institute – Cancer Statistics 2026
